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Chronic lymphocyticleukemia (CLL) is characterized by the clonal proliferation
ofB lymphocytes that are "arrested" at the intermediate stage oftheir differentiation
(1). B cells isolated from CLL (B-CLL) display surface Igs (typically p., sometimes
p and b, and rarely y or a) bearing the same idiotype and L chain type (a or X,
never both). The hallmark ofB-CLL cells is the expression ofCD5 antigen at their
surface. CD5+ B cells constitute a minor subpopulation of normal adult PBMC
(1-6%) (2). B-CLL cells are not irreversibly frozen at an immature level ofthe B
cell development; they differentiate into IgM-secreting cells upon stimulation with
phorbol esters (3, 4), polyclonal B cell activators (5), and less frequently, under the
influence ofIFNs (y, a, or fl) (6) or IL-2 (7). However, the ability ofB-CLL cells
to undergo a y H chain class switching is a controversial issue (8, 9).
IL-4 is a potent inducer ofhuman IgE synthesis by normal PBMC (10). In the
rodent system, IL-4 has been shown to cause the isotype switching to IgE (11).
Nevertheless, the IgE precursors cells are not well defined. Earlier studies in the
animal modelsuggested that these cells might belong toa discrete B cell subset (12).
Very recently, some authors reported the cloning and the molecular characteriza-
tion ofhuman IgE-committed B cells (13). Their conclusion supports the previous
view that these cells do represent a unique B cell sublineage. In the present paper,
we examined theabilityofCD5 malignant B cells todifferentiate into IgE-secreting
cells in response to IL-4. The results indicate that hydrocortisone (HC) is required
together with IL-4 to trigger an IgE response by CLL lymphocytes.
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Cells Culture.
￿
15 untreated CLL patients, classified according to Rai staging (14.), were
selectedforthisstudy. Thebloodlevels oftheirmonoclonal Blymphocytesranged from 1.2 x
104 to 105 cells/mm3. Normal adult volunteers were used as controls. PBMC wereseparated
by density gradient centrifugation as previously described (10).
PBMC were cultured at a concentration of106/ml in 96-well flat-bottomed plates in HB101
medium (HanaBiologics, Berkeley, CA) supplemented with 5% FCS (Gibco Laboratories,
Grand Island, NY). rIL-4, obtained from either Genzyme (Boston, MA) or from Dr. H.
Hofstetter (Ciba Geigy, Switzerland), was used at the concentration of400 U/ml. HC was
used at concentrations ranging from 10-4 to 10-7 M(Sigma Chemical Co., St. Louis, MO)
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and cycloheximide (CHX) (Sigma Chemical Co.) was used at 100,ug/ml. After a 12-d culture,
cell viability was -95%, except in the cultures supplemented with CHX.
Immunofluorescence.
￿
Fresh CLL cells were stained for surface Ig L chain (SIg') and CD5
and CD23 antigen expression using FITC-F(ab)2 goat anti-human is or X (Tago Inc., Burlin-
game, CA), at a dilution of 1 :100, and phycoerythrin-conjugated anti-CD5 (Becton Dickin-
son & Co., Mountain View, CA), and biotinylated anti-CD23, followed by FITC-avidine
at a dilution of 1 :50, respectively. The proportion of stained cells (percent) was measured
by flow cytometry (FACScan; Becton Dickinson & Co.). For the detection of intracytoplasmic
IgE (IC* IgE), PBMC from the same CLL patients were cultured in the presence of a mix-
ture of IL-4 (400 U/ml) and HC (10-5 M). After 12 d, the cells were washed, cytocentrifuged
onto microscope slides, fixed in ice-cold methanol, and stained with anti-IgE mAb (clone
4.15) (a gift from Dr. Saxon, UCLA) at 5 lAg/ml, followed by FITC-F(ab')2 goat anti-mouse
Ig (Tago Inc.) at the dilution of 1 :40. Fluorescent cellswere quantified using a fluorescence
microscope (E. Leitz, Inc., Rockleigh, NJ) (apochrome; 63 x objective).
RIAs.
￿
Total IgE, in the various culture supernatants (CSN), was measured by RIA ex-
actly as previously described (15). Two anti-IgE mAbs were used in this assay. Clone 89 (10
pg/ml), produced in our laboratory, was used to coat the wells of microtitre plate and clone
4.15, as '251-labeled mAb. The sensitivity of the assay was of 0.2 ng/ml. Specific IgE X and
Kwere also measured by RIA. For this assay, the plates were coated with anti-IgE mAb (clone
89). After blocking, the CSN were allowed to incubate for 16 h. After washing, wells were
incubated overnight with 1251-radiolabeled F(ab')2 goat anti-human K or k (Tago Inc.),
washed, and counted. IgE X (present in the CSN of the U266 IgE myeloma cell line) and
IgE is (isolated from the serum of the IgE myeloma patient ADZ and kindly given by Dr.
A. L. de Weck, Switzerland) were used as standards and as specificity controls for the respec-
tive assay.
Results
CLL Lymphocytes Synthesize IgE when Stimulated with IL-4 and HC.
￿
Mononuclear
cells from 11 of 15 CLL patients synthesize IgE in response to a mixture of IL-4
and HC (Table I). The level of IgE production ranges from 1.3 to 54 ng/ml and
does not correlate with the number of circulating lymphocytes. The other classes
of Ig are not induced in the same cultures (data not shown). It is important to note
that CLL cells do not produce IgE in response to either IL-4 (up to 10,000 U/ml)
or HC used alone. The concentrations of IL-4 (400 U/ml) and of HC (10-5 M) used
in these experiments have been selected in preliminary dose-response studies. The
four nonresponder patients have been tested twice with negative results, whereas
all responders have been tested three consecutive times at a 1-mo interval with posi-
tive results. Neither clinical stage nor lymphocyte count can differentiate IgE
responders from nonresponders. Moreover, the two groups of patients display similar
immunological parameters, i.e., same K/X distribution, similar range ofCD5 expres-
sion (80-95% positive cells), and CD23 expression (60-85% positive cells). In con-
trast, normal PBMC synthesize IgE upon stimulation with IL-4 alone and this re-
sponse is enhanced by HC (Table II). The following observations indicate that the
IgE detected in the CSN of CLL cells is not preformed or of extrinsic origin: (a)
IgE cannot be detected in the CSN of either unstimulated cells or of cells costimu-
lated with IL-4 and HC and supplemented with cycloheximide, a protein synthesis
inhibitor (Table I); and (b) the IL-4- and HC-stimulated cultures contain cells with
intracytoplasmic IgE (Ic' IgE) (Table III).
CLL Lymphocytes SynthesizeMonoclonal IgE.
￿
As indicated in Table III, the costimu-
lation with IL-4 and HC induces the tumor cell population and most likely not the con-
taminating normal B cells to synthesize IgE. Indeed, all the secreted IgE moleculesSARFATI ET AL.
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TABLE I
IgE Synthesis by PBMCfrom CLL Patients
Freshly isolated PBMC from CLL patients were stained for surface Ig L chain expression (sIg') using FITC-
F(ab')2 goat anti-human is or X. Stained cells were counted using a FACS analyser (Becton Dickinson & Co.).
PBMC from the same CLL patients were also cultured in the presence of IL-4 (400 U/ml) and/or HC (10-5
M), as indicated in Materials and Methods. After a 12-d culture, CSN were collected and IgE was measured
by RIA, as described in Materials and Methods. The data are the mean values of eight replicate cultures.
The coefficient of variation was <20% . No IgE was detected in IL-4- and HC-stimulated cultures in the
presence of CHX (100 ug/ml).
express the sameL chain type as the freshly isolated monoclonal CD5+ B-CLLcells.
The RIAs for the detection ofIgE tc and IgEX are highly specific. Up to 250 ng/ml
ofIgE A gives background cpm levels ( t 500 cpm; total count, 2 x 105 cpm) when
reacted with 1251-anti-u antibody, and similarly, IgE u does not bind to 1251-anti-A
antibody. Moreover, the IL-4-induced IgE produced by normal PBMC is made of
a mixture of IgE rc and IgE X (data not shown).
TABLE II
Influence of HC on the IL-4-induced IgE Synthesis by Normal PBMC
PBMC from normal volunteers were cultured with IL-4 (400 U/ml) and vari-
ous concentrations of HC (10- 4 to 10- 7 M). The data are the mean values of
eight replicate cultures.
Patients
Rai
stage
White blood cells/
lymphocytes
(x 103/mm3)1%
sIg Medium IL-4 HC
IgE
IL-4 + HC
ng/ml
IL-4 + HC
+ CHX
1 0 28/73 is 0 0 0 2 .5 0
2 III 110/97 K 0 0 0 1 .8 0
3 IV 92/98 X 0 0 0 1 .3 0
4 0 24/75 x 0 0 0 17 .5 0
5 I 56/98 K 0 0 0 1 .4 0
6 I 19/61 x 0 0 0 54.0 0
7 0 27/55 rc 0 0 0 17 .0 0
8 I 66/87 x 0 0 0 5.7 0
9 0 20/84 K 0 0 0 19.0 0
10 0 15/80 K 0 0 0 4.3 0
11 II 22/70 x 0 0 0 52 .0 0
12 0 12/70 K 0 0 0 0 0
13 II 85/83 a 0 0 0 0 0
14 0 24/72 x 0 0 0 0 0
15 II 42/84 rc 0 0 0 0 0
Added to cultures Exp. 1 Exp. 2
IgE
Exp. 3
ng/ml
Exp. 4
- 0 0.1 0.4 0
IL-4 25 15 5.5 8.6
IL-4 + HC 10-4 M 37 37 9.6 13.6
IL-4 + HC 10-5 M 48 79 32 48
IL-4 + HC 10-6 M 46 90 33 44
IL-4 + HC 10- ' M 23 52 35 111778
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TABLE III
Monoclonal IgE Production by CLL Lymphocytes Stimulated by IL-4 and HC
CLL PBMC from four CLL patients were stained for SIg+ L chain and CD5 expression, as
described in Materials and Methods. The same cells were also cultured with IL-4 and HC.
After 12 d, cells were fixed and stained for the presence of intracytoplasmic e chain (Ic' IgE)
using anti-IgE mAb; CSN were tested by RIA for the measurement of total IgE and IgE K
or IgE X, as detailed in Materials and Methods.
Discussion
This study indicates that B-CLL cells are capable of differentiating into mono-
clonal IgE-producing cells and that, in contrast to normal PBMC, both IL-4 and
HC arerequiredtotriggerIgE synthesis. The mechanisms underlyingthe apparent
permissive effect ofglucocorticosteroids (GCS) on the response ofB-CLLs to IL-4,
as well as theirenhancing activity ofthe IL-4-induced IgE synthesis by normal lym-
phocytes, are currentlyinvestigated. The influence ofGCS on humanIgE synthesis
isnot welldocumented, and contradictoryreportshave been published (16, 17). How-
ever, physiological concentrations of GCS were reported to induce Ig production
(IgG, IgA, and IgM) by purified normal B cells in the presence ofmonocytes and
T-replacing factor for steroids (TRFS). TRFS is a 40-kD protein produced by
CD4+ Tcells upon incubation with GCS and IL-1 (18). GCS can also induce the
differentiation of B-CLLs into IgM-producing cells after activation with Staphylo-
coccus aureus Cowan 1 and IL-2, in theabsenceofTcells but in thepresence ofmono-
cytes. The latter may be replaced by IL-1 and IL-6 (19). These data suggest that
GCS act by modulating monocyte-B cell interactions. Asimilar mechanism might
account fortheirpotentiatingor"permissive"effect on IgE synthesisbynormal PBMC
and B-CLLs, respectively. Indeed, it was recently shown that the IL-4-induced syn-
thesis by normal PBMC is IL-6dependent (20), and that B-CLL cells constitutively
produce IL-6 (21).
Since the patients included in this study have been tested more than once with
the sameresults, theymaybegrouped into IgE responders and nonresponders. The
two groups donotdiffer byclinicalorhematologicalparameters. Forexample, PBMC
from all the CLL patients contain >80% CD5+ B cells and from 60 to 85% CD23 +
B cells, Moreover, none ofthe patients have received prior chemotherapy, including
GCS. Itistherefore anticipated that analysisofthe phenotypicand functionalchar-
acteristicsofthe B-CLLs from these two groups ofpatients will generate basic infor-
mation regarding IgE precursor B cells and/or the cellular interactions leading to
their differentiationintoIgE-secretingcells. As such, thepresentstudymaybe viewed
Patient Rai Stage CD5+ SIg+ (x/X) ToT IgE IgE K IgE X Ic+ IgE
To 51 0 ng/ml ng/ml ng/ml
7 0 86 95/0 17 16 0 ND
9 0 85 95/0 20 19 0 ND
10 0 90 85/0 2.7 3 0 5
11 II 96 90/0 52 51 0 6
Standards
IgE X (250 ng/ml) 0 248
IgE K (250 ng/ml) 240 0SARFATI ET AL.
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as a new modelfor the analysis ofthe molecular and cellular mechanisms regulating
IgE synthesis. Indeed, our data strongly suggest that IL-4 and/or HC causes B-CLLs
to switch to IgE. This hypothesis is supported by the recent demonstration by Lebman
and Coffman (11) that IL-4 induces e H chain switching in Th2-stimulated clonal
murine B cell cultures. Finally, the utilization ofthis novel system to study IgE regu-
lation by monoclonal human B cells presents major advantages over the use of normal
PBMC in that it provides access to IgE precursor cells (a) in large quantity; (b) in
a homogeneous stage of maturation; and (c) in a highly purified form.
Summary
The present results indicate that B cellsisolated from chronic lymphocytic leukemia
(B-CLL) from 11 of 14 patients are capable ofspecifically producing IgE upon costimu-
lation with IL-4 and hydrocortisone (HC). IgE is detected by intracytoplasmic fluores-
cence staining and by RIA. Clinical, hematological, and immunological parameters
(including Rai stage, WBC, Lc, SIg K/X, CD5, and CD23 expression) cannot distin-
guish the IgE responder from the nonresponder patients. IL-4 alone is a potent in-
ducer of human IgE synthesis by normal PBMC and we show here that its effect
is strikingly enhanced by HC. The IgE produced by B-CLLs are monoclonal since
they display the same L chain type as the freshly isolated CD5+ B-CLLs. We, there-
fore, conclude that the combination of IL-4 and HC can abrogate the maturation
arrest of CD5+ B-CLLs by inducing their differentiation into IgE-producing cells.
The present data provide a unique model to study the isotype switching to IgE and
the regulation of human IgE synthesis by monoclonal human B cells.
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